Associate Professor
University of Florida, Florida, United States
Dr. Cristofoletti is an Associate Professor in the University of Florida (UF) Department of Pharmaceutics and the Associate Director of the Center for Pharmacometrics and Systems Pharmacology at UF. Before joining the Gator Nation, he served for 15 years as a regulator in Clinical Pharmacology Office at the Brazilian Drug Regulatory Agency (Anvisa). He received his B.S. in Pharmaceutical Sciences from the University of São Paulo, Brazil, in 2004. Dr. Cristofoletti received his Ph.D., summa cum laude, from Johann Wolfgang Goethe University, Frankfurt am Main, Germany, in 2017. He is an Associate Editor of Frontiers in Pharmacology and a member of the editorial boards of AAPS J, Journal of Personalized Medicine, Journal of Pharmacy & Pharmacology, and Biopharmaceutics & Drug Disposition. He also serves as a grant reviewer for the NIH—Advancing Therapeutics study section (MCST-M [81]); the NIH—New Approach Methodologies study section (MCST-U72); the Swiss National Science Foundation; the Maryland Industrial Partnerships Program; and the Austrian Science Fund (FWF).
Dr. Cristofoletti’s lab focuses on developing and using human-relevant, microphysiological systems to model cancer and infectious diseases, reducing the use of animals in research. His research interests include integrating in vitro and in silico mechanistic models (PBPK and QSP) with machine learning to support translational research at early stages of drug development. The lab is also interested in developing vascularized organoids, stem-cell biology, microfluidics, and 3D bioprinting. Dr. Cristofoletti has published more than 100 peer-reviewed articles in highly respected journals in the pharmaceutical sciences. During 2020–2025, his lab contributed to the generation of a grand total of approximately $7,000,000 in extramural funding from federal sources (e.g., six FDA grants, one NIAID grant, and one NIAID contract), not-for-profit foundations (e.g., the Gates Foundation), and private sponsors (e.g., Janssen, Roche, Simulations Plus, Certara, and Libbs Farmacêutica).
Disclosure information not submitted.
Monday, October 20, 2025
3:00 PM - 3:30 PM MDT